Lecanemab Effective in Clearing Amyloid in Early Alzheimer’s

Posted by & filed under Uncategorized.

safety-lane.com 07105
chiropractic-lane.com
https://bit.ly/3oxwDrH
NEWARK
http://www.healthy-lane.com/

Lecanemab Effective in Clearing Amyloid in Early Alzheimer’s

The monoclonal antibody lecanemab, taken at a bi-weekly dose of 10 mg/kg,  completely cleared amyloid within 18 months in 80% patients with early Alzheimer’s disease (AD), results of a phase 2b study show.

“These data show lecanemab removes plaque quite quickly,” Michael Irizarry, MD, vice president of clinical development for neurology at Eisai, the drug’s manufacturer, told Medscape Medical News.

Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively targets amyloid beta (Aβ) protofibrils.

In addition, amyloid clearance appears to correlate with a slowing of cognitive decline, suggesting the drug has an impact on the disease process.

The findings were presented at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference.

14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference: Late-breaking readout Roundtable 5. Presented November 10, 2021.

via Blogger https://bit.ly/3CQexVB